Department of Biotechnology, School of Life Science and Biotechnology, Adamas University, Kolkata, West Bengal, India.
Institute for Skeletal Aging & Orthopedic Surgery, Hallym University-Chuncheon Sacred Heart Hospital, Chuncheon-si, Gangwon-do, Republic of Korea.
mBio. 2021 Aug 31;12(4):e0114021. doi: 10.1128/mBio.01140-21.
The recent emergence of multiple variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a significant concern for public health worldwide. New variants have been classified either as variants of concern (VOCs) or variants of interest (VOIs) by the CDC (USA) and WHO. The VOCs include lineages such as B.1.1.7 (20I/501Y.V1 variant), P.1 (20J/501Y.V3 variant), B.1.351 (20H/501Y.V2 variant), and B.1.617.2. In contrast, the VOI category includes B.1.525, B.1.526, P.2, and B.1.427/B.1.429. The WHO provided the alert for last two variants (P.2 and B.1.427/B.1.429) and labeled them for further monitoring. As per the WHO, these variants can be reclassified due to their status at a particular time. At the same time, the CDC (USA) has marked these two variants as VOIs up through today. This article analyzes the evolutionary patterns of all these emerging variants, as well as their geographical distributions and transmission patterns, including the circulating frequency, entropy diversity, and mutational event diversity throughout the genomes of all SARS-CoV-2 lineages. The transmission pattern was observed highest in the B.1.1.7 lineage. Our frequency evaluation found that this lineage achieved 100% frequency in early October 2020. We also critically evaluated the above emerging variants mutational landscape and significant spike protein mutations (E484K, K417T/N, N501Y, and D614G) impacting public health. Finally, the effectiveness of vaccines against newly SARS-CoV-2 variants was also analyzed. Irrespective of the aggressive vaccination drive, the newly emerging multiple SARS-CoV-2 variants are causing havoc in several countries. As per the CDC (USA) and WHO, the VOCs include the B.1.1.7, P.1, B.1.351, and B.1.617.2 lineages, while the VOIs include the B.1.525, B.1.526, P.2, and B.1.427/B.1.429 lineages. This study analyzed the evolutionary patterns, geographical distributions and transmission patterns, circulating frequency, entropy diversity, and mutational event diversity throughout the genome of significant SARS-CoV-2 lineages. A higher transmission pattern was observed for the B.1.1.7 variant. The study also evaluated the mutational landscape and important spike protein mutations (E484K, K417T/N, N501Y, and D614G) of all of the above variants. Finally, a survey was performed on the efficacy of vaccines against these variants from the previously published literature. The results presented in this article will help design future countrywide pandemic planning strategies for the emerging variants, next-generation vaccine development using alternative wild-type antigens and significant viral antigens, and immediate planning for ongoing vaccination programs worldwide.
最近出现的多种严重急性呼吸系统综合症冠状病毒 2(SARS-CoV-2)变体引起了全球公共卫生的关注。美国疾病控制与预防中心(CDC)和世界卫生组织(WHO)将新变体分为关注变体(VOC)或感兴趣变体(VOI)。VOC 包括 B.1.1.7(20I/501Y.V1 变体)、P.1(20J/501Y.V3 变体)、B.1.351(20H/501Y.V2 变体)和 B.1.617.2。相比之下,VOI 类别包括 B.1.525、B.1.526、P.2 和 B.1.427/B.1.429。WHO 对后两种变体(P.2 和 B.1.427/B.1.429)发出警报,并将其标记为进一步监测。根据 WHO 的说法,这些变体可能因其在特定时间的地位而重新分类。同时,CDC(美国)今天之前将这两种变体标记为 VOI。本文分析了所有这些新兴变体的进化模式,以及它们的地理分布和传播模式,包括所有 SARS-CoV-2 谱系基因组中的循环频率、熵多样性和突变事件多样性。B.1.1.7 谱系的传播模式最高。我们的频率评估发现,该谱系在 2020 年 10 月初达到 100%的频率。我们还对上述新兴变体的突变景观和对公共卫生产生重大影响的刺突蛋白突变(E484K、K417T/N、N501Y 和 D614G)进行了批判性评估。最后,还分析了疫苗对新 SARS-CoV-2 变体的有效性。尽管采取了积极的疫苗接种措施,但新出现的多种 SARS-CoV-2 变体仍在多个国家造成严重破坏。根据 CDC(美国)和 WHO 的说法,VOC 包括 B.1.1.7、P.1、B.1.351 和 B.1.617.2 谱系,而 VOI 包括 B.1.525、B.1.526、P.2 和 B.1.427/B.1.429 谱系。本研究分析了重要 SARS-CoV-2 谱系基因组中的进化模式、地理分布和传播模式、循环频率、熵多样性和突变事件多样性。B.1.1.7 变体的传播模式更高。该研究还评估了所有上述变体的突变景观和重要的刺突蛋白突变(E484K、K417T/N、N501Y 和 D614G)。最后,从已发表的文献中对这些变体的疫苗效力进行了调查。本文介绍的结果将有助于设计针对新兴变体的全国大流行规划策略,使用替代野生型抗原和重要病毒抗原的下一代疫苗开发,以及全球正在进行的疫苗接种计划的即时规划。